Hydroxyurea vs placebo
Measures of ANC · people with sickle cell disease
1 finding from 1 review
- no estimate extracted4 studies · 724 participantsModerate
Findings
What do systematic reviews say?
697 questions · 708 findings · 47 reviews · Cystic Fibrosis and Genetic Disorders
No studies found 263 · 37.1%GRADE not reported 12 · 1.7%Very low 146 · 20.6%Low 168 · 23.7%Moderate 98 · 13.8%High 21 · 3%
Hydroxyurea vs placebo
Health status and quality of life · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 277 participantsLow
Hydroxyurea vs placebo
Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease
1 finding from 1 review
- no estimate extracted5 studies · 784 participantsLow
Appetite stimulants vs placebo
Change in weight (kg) · adults and children with cystic fibrosis
2 findings from 1 review
- no estimate extracted2 studies · 42 participantsLow
- no estimate extracted1 study · 17 participantsLow
Appetite stimulants vs placebo
Change in weight z score · adults and children with cystic fibrosis
2 findings from 1 review
- no estimate extracted3 studies · 40 participantsLow
- no estimate extracted1 study · 17 participantsLow
Appetite stimulants vs placebo
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
- no estimate extracted2 studies · 42 participantsLow
- no estimate extracted1 study · 17 participantsLow
Appetite stimulants vs placebo
Increase in appetite (subjective reporting) · adults and children with cystic fibrosis
Appetite stimulants may leads to higher increase in appetite (subjective reporting) compared with placebo (low certainty).
1 finding from 1 review
- OR 45.25 [3.57, 573.33]2 studies · 23 participantsLow
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 25 participantsVery low
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 25 participantsLow
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Growth · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Exacerbation frequency · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Adverse effects of treatment · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyOR 3 [0.11, 79.91]1 study · 29 participantsLow
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyOR 1.63 [0.19, 13.93]1 study · 25 participantsLow
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Colchicine (oral) vs placebo
Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyRR 0.21 [0.05, 0.95]1 study · 10 participantsLow
Rilonacept vs placebo
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Rilonacept vs placebo
Adverse drug reactions · people with familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 14 participantsLow
Rilonacept vs placebo
Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 14 participantsLow
ImmunoGuard vs placebo
Number of participants experiencing an attacka · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
ImmunoGuard vs placebo
Duration of attacks · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found